Norditropin Nordiflex (Somatropin)

Somatropin, the active ingredient in Norditropin Nordiflex, is a growth hormone presented as a solution for injection (pen injector) for subcutaneous use. It is indicated for treating growth hormone deficiency in children and adults, as well as growth disorders associated with genetic syndromes such as Turner and Prader‑Willi, and promotes normal growth of bone and muscle tissue.

GNH USA supplies Norditropin Nordiflex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Norditropin Nordiflex, a recombinant human growth hormone, is used to manage conditions related to growth hormone deficiency and associated growth disorders. - Growth hormone deficiency in children: stimulates linear growth and increases height velocity. - Growth hormone deficiency in adults: improves body composition, bone density, and metabolic profile. - Turner syndrome: enhances stature gain during puberty. - Prader‑Willi syndrome: supports growth and improves body composition. - Chronic renal insufficiency-associated growth failure: promotes growth in pediatric patients with renal disease. - Idiopathic short stature: facilitates increased growth rate when other causes are excluded.

Somatropin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Headache: transient headache reported by some patients. - Joint stiffness: occasional arthralgia or reduced joint mobility. - Edema: peripheral swelling, especially in the lower extremities.

Serious or Rare Side Effects: - Intracranial hypertension: signs include headache, visual changes, and nausea. - Slipped epiphysis: premature closure of growth plates leading to bone deformities. - Severe allergic reaction: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Hyperglycemia: elevated blood glucose levels, particularly in patients with diabetes risk.

When prescribing or handling Norditropin Nordiflex, several precautions should be observed to ensure safety and efficacy. - Dose titration: adjust the dose based on IGF‑1 levels, growth response, and patient tolerance. - Monitoring: regularly assess glucose metabolism, thyroid function, and growth parameters. - Contraindications: avoid use in patients with active malignancy or known hypersensitivity to somatropin. - Pregnancy and lactation: safety has not been established; use only if the potential benefit justifies the risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the pen injector.

Somatropin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Glucocorticoids: may antagonize growth hormone effects and reduce IGF‑1 response. - Oral estrogen therapy: can diminish the anabolic action of growth hormone. - Insulin: concurrent use may increase risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diabetes mellitus: somatropin may exacerbate hyperglycemia; monitor blood glucose. - Thyroid hormone replacement: may require dose adjustments due to altered metabolism.